在经典霍奇金淋巴瘤的一线治疗中处理与 Brentuximab Vedotin 相关的外周神经病。

IF 5.5 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology Pub Date : 2024-09-06 DOI:10.1016/j.critrevonc.2024.104499

Jeremy S. Abramson , Robert Stuver , Alex Herrera , Emily Patterson , Yi-Ping Wen , Alison Moskowitz

{"title":"在经典霍奇金淋巴瘤的一线治疗中处理与 Brentuximab Vedotin 相关的外周神经病。","authors":"Jeremy S. Abramson , Robert Stuver , Alex Herrera , Emily Patterson , Yi-Ping Wen , Alison Moskowitz","doi":"10.1016/j.critrevonc.2024.104499","DOIUrl":null,"url":null,"abstract":"<div><div>The ECHELON-1 trial demonstrated the effectiveness of brentuximab vedotin (BV) in combination with doxorubicin, vinblastine, and dacarbazine as a frontline treatment regimen in classical Hodgkin lymphoma. However, peripheral neuropathy (PN) is common with this regimen, occurring in up to two-thirds of patients. While standard prescribing information recommends BV dose modification at the onset of grade 2 PN, management strategies for PN are not well-defined. Most commonly, clinicians dose reduce or discontinue BV, vinblastine, or both. We review evidence-based and practical approaches for managing peripheral neuropathy, emphasizing early detection and dose modification.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104499"},"PeriodicalIF":5.5000,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1040842824002427/pdfft?md5=00caaee17b8db92492e4a104f49516a0&pid=1-s2.0-S1040842824002427-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma\",\"authors\":\"Jeremy S. Abramson , Robert Stuver , Alex Herrera , Emily Patterson , Yi-Ping Wen , Alison Moskowitz\",\"doi\":\"10.1016/j.critrevonc.2024.104499\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The ECHELON-1 trial demonstrated the effectiveness of brentuximab vedotin (BV) in combination with doxorubicin, vinblastine, and dacarbazine as a frontline treatment regimen in classical Hodgkin lymphoma. However, peripheral neuropathy (PN) is common with this regimen, occurring in up to two-thirds of patients. While standard prescribing information recommends BV dose modification at the onset of grade 2 PN, management strategies for PN are not well-defined. Most commonly, clinicians dose reduce or discontinue BV, vinblastine, or both. We review evidence-based and practical approaches for managing peripheral neuropathy, emphasizing early detection and dose modification.</div></div>\",\"PeriodicalId\":11358,\"journal\":{\"name\":\"Critical reviews in oncology/hematology\",\"volume\":\"204 \",\"pages\":\"Article 104499\"},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2024-09-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1040842824002427/pdfft?md5=00caaee17b8db92492e4a104f49516a0&pid=1-s2.0-S1040842824002427-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Critical reviews in oncology/hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1040842824002427\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842824002427","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

ECHELON-1 试验证明了布伦妥昔单抗维多汀（BV）联合多柔比星、长春新碱和达卡巴嗪作为经典霍奇金淋巴瘤一线治疗方案的有效性。然而，外周神经病变（PN）在这种治疗方案中很常见，多达三分之二的患者会出现这种情况。虽然标准处方信息建议在出现 2 级 PN 时调整 BV 的剂量，但 PN 的治疗策略尚未明确。最常见的情况是，临床医生减少 BV 剂量或停用 BV、长春新碱或两者。我们回顾了管理周围神经病变的循证实用方法，强调早期检测和剂量调整。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma

The ECHELON-1 trial demonstrated the effectiveness of brentuximab vedotin (BV) in combination with doxorubicin, vinblastine, and dacarbazine as a frontline treatment regimen in classical Hodgkin lymphoma. However, peripheral neuropathy (PN) is common with this regimen, occurring in up to two-thirds of patients. While standard prescribing information recommends BV dose modification at the onset of grade 2 PN, management strategies for PN are not well-defined. Most commonly, clinicians dose reduce or discontinue BV, vinblastine, or both. We review evidence-based and practical approaches for managing peripheral neuropathy, emphasizing early detection and dose modification.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.